Neuland Laboratories' Q1 FY 2025-26 Quarterly Results
- 31 Jul 2025
Result Summary
- Neuland Laboratories Ltd reported a 23.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 32.4%.
- Its expenses for the quarter were down by 5.1% QoQ and 15.6% YoY.
- The net profit decreased 79.4% QoQ and decreased 85.8% YoY.
- The earnings per share (EPS) of Neuland Laboratories Ltd stood at 10.8 during Q1 FY 2025-26.
Financial Statments for Q1 FY 2025-26
| (₹ crores) | Q1FY26 | Q4FY25 | Q1FY25 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 300.61 | 390.37 | 444.41 | -23.0% | -32.4% |
Total Expenses | 283.03 | 298.16 | 335.19 | -5.1% | -15.6% |
Profit Before Tax | 17.57 | 92.20 | 129.84 | -80.9% | -86.5% |
Tax | 3.67 | 24.64 | 31.97 | -85.1% | -88.5% |
Profit After Tax | 13.90 | 67.56 | 97.87 | -79.4% | -85.8% |
Earnings Per Share | 10.80 | 52.70 | 76.30 | -79.5% | -85.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Neuland Laboratories Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the manufacturing of active pharmaceutical ingredients (APIs). The company is known for its extensive portfolio of generic and custom APIs, which cater to a wide range of therapeutic categories. Neuland Laboratories serves global pharmaceutical companies, providing products that are integral to the formulation of medications. As of the latest available information, the company has been focusing on expanding its manufacturing capabilities and enhancing its R&D efforts to cater to the evolving demands of the pharmaceutical market. Any recent major developments or strategic initiatives beyond this scope are not available in the provided data.
Revenue
For Q1FY26, Neuland Laboratories Ltd reported a total income of ₹300.61 crores. This represents a decline in revenue both on a quarter-over-quarter (QoQ) basis by 23.0% from ₹390.37 crores in Q4FY25, and on a year-over-year (YoY) basis by 32.4% from ₹444.41 crores in Q1FY25. The decrease in total income is reflected in both comparisons, indicating a downward trend in revenue over the periods considered. No additional information on the specific factors impacting revenue is provided.
Profitability
The profitability metrics for Neuland Laboratories Ltd show notable changes over the observed periods. The company recorded a Profit Before Tax (PBT) of ₹17.57 crores in Q1FY26, which signifies a significant reduction of 80.9% QoQ from ₹92.20 crores in Q4FY25 and an 86.5% decrease YoY from ₹129.84 crores in Q1FY25. Similarly, the Profit After Tax (PAT) for Q1FY26 stood at ₹13.90 crores, down by 79.4% QoQ from ₹67.56 crores in Q4FY25, and down 85.8% YoY from ₹97.87 crores in Q1FY25. Earnings Per Share (EPS) followed a parallel trend, decreasing to ₹10.80 in Q1FY26 from ₹52.70 in Q4FY25 and ₹76.30 in Q1FY25, depicting a consistent decline over these periods.
Operating Metrics
Neuland Laboratories Ltd's total expenses for Q1FY26 were ₹283.03 crores, showing a decrease of 5.1% QoQ from ₹298.16 crores in Q4FY25 and a 15.6% decrease YoY from ₹335.19 crores in Q1FY25. The tax expense for Q1FY26 was ₹3.67 crores, marking an 85.1% reduction QoQ from ₹24.64 crores in Q4FY25, and an 88.5% decrease YoY from ₹31.97 crores in Q1FY25. These figures highlight a substantial reduction in expenses and tax liabilities across both QoQ and YoY comparisons, which is aligned with the trends in revenue and profitability metrics. No further details on operational efficiency or other financial ratios are provided in the data.
FAQs
When was Neuland Laboratories Ltd Q1 FY 2025-26 result announced?
Neuland Laboratories Ltd announced its Q1 FY 2025-26 results on 31 July, 2025.
What are Neuland Laboratories Ltd quarterly results?
Neuland Laboratories Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
What were the key highlights of Neuland Laboratories Ltd Q1 FY 2025-26 results?
Key highlights of Neuland Laboratories Ltd Q1 FY 2025-26 results include:
- Revenue: ₹300.61 crore
- Net Profit: ₹13.90 crore
- EBITDA: ₹42.34 crore
- Year-over-Year Growth: -32.4%
- Quarter-over-Quarter Growth: -23.0%
How did Neuland Laboratories Ltd net profit perform in this quarter?
Neuland Laboratories Ltd reported a net loss of ₹13.90 crore in Q1 FY 2025-26, reflecting a -85.8% year-over-year growth.
What was Neuland Laboratories Ltd revenue in Q1 FY 2025-26?
Neuland Laboratories Ltd posted a revenue of ₹300.61 crore in Q1 FY 2025-26.